BDI Partners with Clinical Implementation Specialist Company..."Ellison Anticancer Drug Phase 3 Clinical Trial Gains Momentum"

[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 22nd that it has signed a joint development partnership with PlatBio, led by Dr. Sunjin Kim, known as the foremost authority among clinical implementation experts, to revitalize its bio business division.

Through this agreement, PlatBio will play a key partner role with VIDI and the U.S.-based Allison Pharmaceuticals (Allison). In particular, VIDI expects that various anticancer new drugs, including Glufosfamide, a pancreatic cancer drug currently in Phase 3 clinical trials by Allison, will gain significant momentum through PlatBio’s clinical implementation translational research.

Dr. Sunjin Kim, CEO of PlatBio, earned his Ph.D. from Seoul National University Graduate School and served as a professor at the MD Anderson Cancer Center, part of the University of Texas, known as one of the world’s top cancer centers, for 19 years. During his tenure, he published over 100 papers. Notably, Dr. Kim has experience designing and successfully completing clinical trials for approximately 12 anticancer new drugs.

Clinical implementation translational research refers to consulting on the development process, including preclinical trials of new drug candidates, and planning and conducting customized clinical trials. By structuring clinical designs, it is possible to understand the characteristics of new substances from the laboratory stage and significantly improve the chances of clinical trial success and commercialization.

Additionally, substances that failed in clinical trials or those successfully commercialized for other indications can be repositioned by developing new clinical designs, new clinical indications, and dosages through preclinical trials. This approach can reduce the discovery period of new drug substances, which typically takes about 10 years, to 3 to 5 years.

A VIDI official stated, “Last year, Dr. Kim joined Kolon TissueGene and led the resumption of Phase 3 clinical trials for Invossa, which had been put on hold by the FDA, earning him the reputation of ‘God’s Hand.’ Through joint development collaboration utilizing Dr. Kim’s experience and PlatBio’s industry-leading clinical implementation translational research capabilities, VIDI will quickly establish itself as a leader in the field of bio new drug development.”

He added, “Among new drugs that have received FDA approval and reached commercialization, about 30% are approved through drug repositioning. VIDI plans to focus on this area by fully leveraging PlatBio’s proven drug repositioning capabilities. Currently, we are coordinating specific acquisition negotiations with a pharmaceutical company that holds a failed new drug at the clinical stage.”

This content was produced with the assistance of AI translation services.